Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis

Thrombosis Research

Volumn 98, Issue 6, 2000, Pages 531-540

  Rebello, Sam S ^a   Blank, Howard S ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Coronary thrombolysis; Factor Xa inhibitor; Platelets; Reperfusion; rNAP5

Indexed keywords

ALTEPLASE; ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 10A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DRUG EFFICACY; HEMODYNAMICS; HEMOSTASIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTITHROMBIN III; BLOOD COAGULATION TESTS; BLOOD FLOW VELOCITY; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; DOGS; FIBRINOLYTIC AGENTS; HELMINTH PROTEINS; MYOCARDIAL INFARCTION; RECOMBINANT PROTEINS; REPERFUSION; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0034659469     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00210-3     Document Type: Article

References (23)

1. Moliterno D.J., Topol E.J. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thromb Haemost. 78:1997;214-219.
2. Nicolini F.A., Lee P., Malycky J.L., Lefkovits J., Kottke-Marchant K., Plow E.F., Topol E.J. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis. 7:1996;39-48.
3. Maki A., Shirato C., Ohguchi M., Aoki N., Ochiai N., Taguchi S., Aoki I., Ishikawa K. Mechanism of rethrombosis after thrombolytic therapy. angioscopic findings and investigation of the coagulation system in dogs Angiology. 49(6):1998;447-453.
4. Scharfstein J.S., Abendschein D.R., Eisenberg P.R., George D., Cannon C.P., Becker R.C., Sobel B., Cupples L.A., Braunwald E., Loscalzo J. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. Am J Cardiol. 78(5):1996;503-510.
5. Reganon E., Ferrando F., Vila V., Villa P., Martinez-Sales V., Fayos L., Ruano M., Aznar J. Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone. Haemostasis. 28(2):1998;99-105.
6. Cappello M., Vlasuk G.P., Bergum P.W., Huang S., Hotez P.J. Ancylostoma caninum anticoagulant peptide. a hookworm-derived inhibitor of human coagulation factor Xa Proc Natl Acad Sci. 92:1995;6152-6156.
7. Stanssens P., Bergum P.W., Gansemans Y., Jespers L., Laroche Y., Huang S., Maki S., Messens J., Lauwereys M., Capello M., Hotez P.J., Laster I., Vlasuk G.P. Anticoagulant repertoire of the hookworm Ancyclostoma caninum. Proc Natl Acad Sci. 93:1996;2149-2154.
8. Rebello S.S., Blank H.S., Rote W.E., Vlasuk G.P., Lucchesi B.R. Antithrombotic efficacy of a novel recombinant nematode anticoagulant peptide (rNAP5), a direct and selective Factor Xa inhibitor, in canine models of thrombosis. J Pharmacol Exp Ther. 283:1997;91-99.
9. Lynch J.J. Jr., Sitko G.R., Mellott M.J., Nutt E.M., Lehman E.D., Friedman P.A., Dunwiddie C.T., Vlasuk G.P. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc Res. 28:1994;78-85.
10. Schaffer L.W., Davidson J.T., Vlasuk G.P., Siegel P.K.S. Antithrombotic efficacy of recombinant tick anticoagulant peptide, a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation. 84:1991;1741-1748.
11. Sitko G.R., Ramjit D.R., Stabilito I.I., Lehman D., Lynch J.L., Vlasuk G.P. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective factor Xa inhibitor, tick anticoagulant peptide. Circulation. 85:1992;805-815.
12. Mellott M.J., Holahan M.A., Lynch J.J., Vlasuk G.P., Dunwiddie C.T. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Circ Res. 70:1992;1152-1160.
13. Schaffer L.W., Davidson J.T., Vlasuk G.P., Dunwiddie C.T., Siegel P.K.S. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscler Thromb Vasc Biol. 12:1992;879-885.
14. Kornowski R., Eldor A., Werber M.M., Ezov N., Zwang E., Nimrod A., Chernine A., Finkelstein A., Panet A., Laniado S., Keren G. Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis. a comparison with heparin and hirudin in a rabbit thrombosis model Cor Art Dis. 7:1996;903-909.
15. Dunwiddie C.T., Smith D.E., Nutt E.M., Vlasuk G.P. Anticoagulant effects of the selective factor Xa inhibitors, tick anticoagulant peptide and antistasin, in the APTT assay are determined by the relative rate of prothrombinase inhibition. Thromb Res. 64:1991;787-794.
16. Nicolini F.A., Nichols W.W., Saldeen T.G., Khan S., Mehta J.L. Adjunctive therapy with low-molecular-weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis. Am Heart J. 124:1992;280-288.
17. Jun L., Arnout J., Vanhove P., Dol F., Lormeau J.C., Herbert J.M., Collen D., Van de Werf F. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. Cor Art Dis. 6(3):1995;257-263.
18. Leadley R.J., Kasiewski C.J., Bostwick J.S., Bentley R., McVey M.J., White F.J., Perrone M.H., Dunwiddie C.T. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rt-PA in the stenosed canine coronary artery. Thromb Haemost. 78:1997;1278-1285.
19. Eisenberg P.R., Sherman L., Rich M., Schwartz D., Schechtman K., Gletman E.M., Sobel B.E., Jaffe A.S. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol. 7:1986;1255-1262.
20. Eisenberg P.R., Sobel B.E., Jaffe A.S. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 19:1992;1065-1069.
21. Eisenberg P.R., Siegel J.E., Abendschein D.R., Miletich J.P. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 91:1993;1877-1883.
22. Herault J.P., Bernat A., Pflieger A.M., Lormwau J.C., Herbert J.M. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther. 283:1997;16-22.
23. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin- activable fibrinolytic inhibitor. J Biol Chem. 270:1995;14477-14484.